$AADI not sure what justifies the sell off here…I didn’t listen to the conference call this am and thought maybe there was something they said there that it is tanking the price. Just finished listening to it and honestly i thought everything they said was right and bullish. Im still in and down %14 on the day but as always trade what you see not what you want to see.
3
2
@DrCipolla Only 100-300 patients annually. Launch planned in Q1 2022. PEComa is a really small market. Upcoming trials (tumor agnostic TSC1/TSC2 mutations) have 10K-15K expected annual patient population. But data there isn't expected until 2024. Didn't quite catch what they expect to price FYARRO at initially in PEComa.
2
2 Likes